Sign in Subscribe
Amino acids

Patent Application for Treating Metabolic Disorders with Antagonistic Binding Proteins for GIPR/GLP-1 Receptor Agonist Fusion Proteins

Strategic Insights

— 2 min read

Researchers have developed a novel approach to treating metabolic disorders by fusing a GLP-1 receptor agonist polypeptide with an antagonist glucose-dependent insulinotropic polypeptide receptor (GIPR) antigen binding protein. This fusion protein has shown promise in reducing body weight, improving insulin sensitivity, and promoting glucose tolerance. According to the patent application, the fusion protein can be administered to individuals with obesity, hyperglycemia, hyperinsulinemia, insulin resistance, and diabetes mellitus.

Key Takeaways:

  • The patent application describes a method for treating metabolic disorders using a fusion protein that combines a GLP-1 receptor agonist polypeptide with an antagonist GIPR antigen binding protein.
  • The fusion protein has shown efficacy in reducing body weight, improving insulin sensitivity, and promoting glucose tolerance in preclinical studies.
  • The patent application claims that the fusion protein can be used to treat various metabolic disorders, including obesity, hyperglycemia, hyperinsulinemia, insulin resistance, and diabetes mellitus.
  • The inventors claim that the fusion protein can be administered to individuals with metabolic disorders to elicit therapeutic effects.
  • The patent application also describes the use of a peptide linker to fuse the C-terminus of the GLP-1 receptor agonist polypeptide to the N-terminus of the antagonist GIPR antigen binding protein.
  • The inventors have identified several embodiments of the fusion protein, including one that comprises a light chain variable domain of the antagonist anti-human GIPR antibody and one that comprises a heavy chain variable domain of the antagonist anti-human GIPR antibody.
  • The patent application also describes the use of a human IgG1 or IgG2 antibody as the antagonist anti-GIPR antibody.

Statistics:

  • The patent application was filed on June 23, 2025, and posted on October 16, 2025.
  • The inventors have claimed that the fusion protein can be used to treat metabolic disorders in individuals with obesity, hyperglycemia, hyperinsulinemia, insulin resistance, and diabetes mellitus.
  • The patent application has identified several embodiments of the fusion protein, including the use of a peptide linker and the use of a light or heavy chain variable domain of the antagonist anti-human GIPR antibody.
  • The patent application has also identified several potential therapeutic applications of the fusion protein, including the treatment of obesity, hyperglycemia, hyperinsulinemia, insulin resistance, and diabetes mellitus.

Sources:

  • HOLDER, Jerry Ryan; LLOYD, David J.; LU, Shu-Chen; STANISLAUS, Shanaka; VENIANT-ELLISON, Murielle M.; WALKER, Kenneth W. Method Of Treating Or Ameliorating Metabolic Disorders Using Antagonistic Binding Proteins For Gastric Inhibitory Peptide Receptor (Gipr)/Glp-1 Receptor Agonist Fusion Proteins. U.S. Patent Application Number 20250319196, filed June 23, 2025 and posted October 16, 2025. Patent URL (for desktop use only): https://ppubs.uspto.gov/pubwebapp/external.html?q=(20250319196)&db=US-PGPUB&type=ids

Read more